Oncotarget

Research Papers:

Prediction of clinical outcome and survival in soft-tissue sarcoma using a ten-lncRNA signature

Rong-quan He, Qing-jun Wei, Rui-xue Tang, Wen-jie Chen, Xia Yang, Zhi-gang Peng, Xiao-hua Hu, Jie Ma _ and Gang Chen

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:80336-80347. https://doi.org/10.18632/oncotarget.18165

Metrics: PDF 1397 views  |   HTML 2819 views  |   ?  


Abstract

Rong-quan He1,*, Qing-jun Wei2,*, Rui-xue Tang3, Wen-jie Chen4, Xia Yang3, Zhi-gang Peng1, Xiao-hua Hu1, Jie Ma1 and Gang Chen3

1Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China

2Department of Orthopaedics Trauma and Hand Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China

3Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China

4Department of Thoracic and Cardiovascular Diseases, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. China

*These authors are contributed equally to this work

Correspondence to:

Jie Ma, email: majie086@163.com

Gang Chen, email: chen_gang_triones@163.com

Keywords: soft-tissue sarcoma, lncRNA, prognosis, RNA-seq, TCGA

Received: January 23, 2017     Accepted: May 10, 2017     Published: May 22, 2017

ABSTRACT

The prognostic value of long non-coding RNAs (lncRNAs) in patients with soft-tissue sarcoma has rarely been unraveled. The aim of the study was to find a lncRNA signature to predict the clinical outcome and survival in soft-tissue sarcoma based on the high-throughput RNA-seq data from The Cancer Genome Atlas (TCGA) database. The lncRNAs which closely correlated with overall survival in 258 soft-tissue sarcoma patients were identified with Cox proportional regression model. Ten lncRNAs, including RP11-560J1.2, AP001432.14, RP4-665J23.1, LINC00680, AC006129.2, RP11-230G5.2, BACH1-IT2, RP11-274B21.9, RP11-504A18.1 and RP11-713P17.3, were selected to calculate a risk score. The risk score could effectively predict patients’ outcome, such as the status of mitotic count of tumor cells, person neoplasm cancer and residual tumor. More inspiringly, the risk score generated from the 10-lncRNA signature was an independent prognostic indicator for soft-tissue sarcoma patients. Overall, this 10-lncRNA signature gains the potential as an effective prognostic tool for soft-tissue sarcoma as part of the integrated clinical RNA-seq program.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18165